Press Releases

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 31, 2026

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 30, 2026

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

May 29, 2026

Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

April 27, 2026

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

April 10, 2026

Replimune to Present at Two Upcoming Investor Conferences

March 2, 2026

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

February 3, 2026